Analyse des Nackentransparenz (NT-)Screeningkonzepts an der Frauenklinik der MHH: Eine prospektive Follow-up-Studie;Erratum: Analysis of the Nuchal Transparency (NT) Screening Concept at the Gynecologocial Clinic of MHH: A Prospective Follow-Up Study (Zeitschrift fur Geburtshilfe und Neonatologie (2006) 210:3 (99-106) DOI: 10.1055/s-2006-941554);Analysis of the nuchal transparency (NT) screening concept at the gynecologocial clinic of MHH: A prospective follow-up study;Analyse des nackentransparenz (NT-)screeningkonzepts an der frauenklinik der MHH: Eine prospektive follow-up-studie

Zeitschrift fur Geburtshilfe und Neonatologie

Volumn 210, Issue 3, 2006, Pages 99-106

  Staboulidou, Ismini ^a   Gunter H H ^a   Steinborn, A ^b   Gebauer, G ^b   Scharf, Alexander ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

First trimester screening; Nuchal translucency; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; FEMALE; FETUS OUTCOME; GYNECOLOGIC CARE; HUMAN; KARYOTYPE; NECK MUSCLE; PREGNANCY OUTCOME; TASK PERFORMANCE;

EID: 33745759011     PISSN: 09482393     EISSN: 14391651     Source Type: Journal    
DOI: 10.1055/s-0035-1549868     Document Type: Erratum

References (29)

1. Schmidtke J. Vererbung und Ererbtes. Reinbeck bei Hamburg: Rowohlt Taschenbuch Verlag GmbH, 1997
2. Wald NJ, Cuckle HS. Recent advances in screening for neural tube defects and Down's syndrome. Ballière's Clin Obstet Gynecol, 1987: 649-676
3. Dornauf leditor. Biochemische Tests. In: Pränataldiagnostik. FertiConsult GmbH, 2002. (Online(. URL: www.gynaktuell.de/text.php37thema = S&artikel = 6&seq = 23&cn = de&la = de
4. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre projekt on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;351:343-346
5. Brambati B, Tului L, Bonacchi I, Shrimanker K, Suzuki Y, Grudzinskas JG. Serum PAPP-A and free β-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 1994; 14: 1043-1047
6. Wald NJ, Kenrard A, Hackshaw AK. First trimester serum screening for Down's Syndrome. Prenat Diagn 1995; 15: 1227-1240
7. Brizot ML, Snijders RJM, Butler J, Bersinger NA, Nicolaides KH. Maternal serum hCG and fetalnuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. BJOG 1995; 102: 127-132
8. De Biasio P, Siccardi M, Volpe G, Famularo L, Santi P, Canini S. First trimester screening for Down's syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy: the combined test. Prenat Diagn 1999; 19: 360-363
9. De Graaf IM, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, van Lith JM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999; 19: 458-462
10. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 2002 Sep; 20(3): 219-25
11. von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A, Pruggmayer M, Kamin G, Fritzer E, Harris C, Arnold N. Screening for trisomy 21 by maternal age, fetal nuchal transluecency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 2002 Aug; 12(2): 89-94
12. Zoppi MA, Ibba RM, Floris M, Monni G. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia. Ultrasound Obstet Gynecol 2001 Dec; 18(6): 649-51
13. Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S, Meyberg H, Kamin G, Germer U, Bielicki M, Hackeloer BJ, Sarlay D, Kuhn P, Klapp J, Bahlmann F, Pruggmayer M, Schneider KT, Seefried W, Fritzer E, von Kaisenberg CS. Screening for trisomy 21 by fetal nuchal transluecency and maternal age: a multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 2001 Dec; 18(6): 645-8
14. Nicolaides KH, Sebire NJ, Snijders RJM. The 11-14-week scan - The diagnosis of fetal abnormalities. New York: The Parthenon Publishing Group Inc., 1999
15. Palomaki G, Haddow JE. Maternal serum a fetoprotein, age and Down syndrome risk. Am J Obstet Gynecol 1987; 156: 460-463
16. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000; 107: 1271-1275
17. Wald NJ, Cuckle HS. Recent advances in screening for neural tube defects and Down's syndrome. Ballière's Clin Obstet Gynecol, 1987: 649-676
18. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Downs syndrome. Prenat Diagn 1997; 17: 821-829
19. Zentrum für Qualitätsmanagement im Gesundheitswesen, eine Einrichtung der Ärztekammer Niedersachsen. Qualitätssicherung Geburtshilfe, Jahresauswertung 2001, Niedersachsen, Vergleichsstatistik Frauenklinik MHH Hannover; 2002.
20. Cuckle HS, Wald NJ, Densem P, Knight GJ, Haddow JE, Palomaki GE, Canick JA. The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. BJOG 1990; 97: 272-276
21. Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH. First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status. Prenat Diagn 2000; 20(10): 852-853
22. Crossley JA, Aitken DA, Waugh SM, Kelly T, Connor JM. Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin and effect on detection of Down syndrome pregnancies in second-trimester screening. Prenat Diagn 2002; 22(3): 247-255
23. Lagerström M, Bremme K, Eneroth P. Maternal serum levels of estriol, prolactin, human placental lactogen and chorionic gonadotrophin related to fetal sex in normal and abnormal pregnancies. Gynecol Obstet Invest 1990; 30: 198-203
24. Spencer K, Aitken DA, Crossley JA, McGraw G, Berry E, Anderson R, Connor JM, Macri JN. First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein an pregnancy associated plasma protein A. Ann Clin Biochem 1994; 31: 447-454
25. Krantz D, Larsen J, Buchanon D, Macri J. First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol 1996; 174: 612-616
26. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy associates plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-237
27. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96: 207-213
28. Bewley S, Roberts LJ, Mackinson AM, Rodeck CH. First trimester nuchal translucency: Problems with screening the general population. 2. BJOG 1995; 102(5): 386-388
29. Nicolaides KH, Brizot ML, Snijders RJM. Fetal nuchal translucency thickness: ultrasound screening for fetal trisomy in first trimester of pregnancy. BJOG 1994; 101: 782-786